ChitogenX, Inc.

Significant unmet medical needs in US $19B burn and skin defects market New patent in US and Canada supports ChitogenX' proprietary chitosan-based biopolymer as ideal combination with cellular regeneration technologies Potential for streamlined regulatory process, and faster path to commercialization Both burn and skin repair program to be primarily funded by recently awarded $3.4 M grant MONTREAL, Nov. 7, 2023 /PRNewswire/ - ChitogenX Inc., (CSE: CHGX) (OTCQB: CHNXF) (" ChitogenX" or the " Company"), a clinical-stage regenerative medicine company, today announced that it has launched a new development program targeting significant unmet medical needs in the burn and skin repair market, currently valued at US $19B and growing at 5% + CAGR through 2032. Proof of concept studies have already been successfully completed and results will be the subject of news releases in the coming weeks. "ChitogenX wishes to leverage positive data in proof-of-concept studies combined with the recently obtained US and Canadian patents for our chitosan-based biopolymer. Burn and skin repair programs potentially allow for efficient clinical trial development program, streamlined regulatory process and faster path to commercialization'', said Philippe Deschamps, President and CEO. ''The Company's proprietary chitosan-based biopolymer is well suited to help address significant unmet medical needs to repair skin defects caused by burns, other trauma and wounds of various aetiologies, alone or in combination with other cellular technologies, due to its unique characteristics allowing it to adhere to tissues thus facilitating the delivery of various therapeutic interventions to its target tissue when compared to standard of care", continued Deschamps. While pursuing its' soft tissue repair programs, ChitogenX believes that targeting the skin integrity market will allow ChitogenX to leverage its ongoing work in the ortho-regenerative market where our technology is being evaluated to deliver therapeutic compounds such as PRP to patients in need. About ChitogenX Inc. ChitogenX Inc. is a clinical stage regenerative medicine company dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary Chitosan Based Biopolymer technology platform, a proprietary muco-adhesive scaffold, specifically designed to be combined with therapeutics to improve tissue repair. Other formulations are being developed to leverage the technology's performance characteristics such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease. Further information about ChitogenX is available on the Company's website at and on SEDAR at . Forward-Looking Statements This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. SOURCE Ortho Regenerative Technologies Inc.

MERRIMACK, N.H., Feb. 2, 2023 /PRNewswire/ -- The Ortho Show, a popular podcast for the orthopedic community, will be under new ownership as of February 1, 2023, with big announcements to follow regarding expansion of both content and the business. Taking the helm alongside Dr. Sigman is Koha Health, an innovative revenue cycle management company focused on supporting orthopedics, ASCs and MSK related practices to achieve total financial health. The Ortho Show was born in 2019 from a passion to share remarkable, insightful, educational and just plain entertaining stories from the world of orthopedics. "Taking ownership of The Ortho Show podcast with Dr. Sigman is an exciting and inspirational challenge for our team," said Brian Hall, president and chief executive officer, Koha Health. "The Ortho Show has quickly become a popular destination to find dedicated content and stories from within the orthopedic community. It is an honor to partner with Dr. Sigman and help take it to new levels." The Ortho Show podcast currently has thousands of listeners per month from over 25 countries and offers a fascinating depth of personal stories from within the orthopedic community. "I am exceptionally proud of the organic growth The Ortho Show has seen over the years," said Dr. Scott Sigman. "With the backing of Koha Health, we will be expanding partnerships with industry, growing our listenership and providing the best possible content in the Orthopedic space." Going forward, The Ortho Show listeners can look forward to more resources, more education, and more content. Additionally, The Ortho Show welcomes industry veteran Beth Best whose marketing expertise will help take The Ortho Show to the next level. Expanded programming starts this April, when The Ortho Show will be podcasting live - for the first time - from Shoulder 360 in Miami. About The Ortho Show The Ortho Show was born in 2019 from a passion to share remarkable, insightful, educational and just plain entertaining stories from the world of orthopedics. About Koha Health Koha Health supports independent orthopedic and musculoskeletal practices in achieving total financial health by addressing both the revenue cycle and strategic concerns that impact organizational value. A Koha Health partnership offers practices access to revenue cycle expertise, patient engagement optimization and strategic advisory services. With more than 30 years of experience, Koha Health is steeped in understanding best practice processes, and has the training and regulatory knowledge necessary to maximize financial performance and build practice value. Through robust tech-enabled services delivered by a global team that makes real investments in culture, Koha Health liberates physicians and owners from the stress of practice management allowing them to achieve their personal and professional goals. To learn more, visit . Contact: Heather Rivenburg Account Executive [email protected] SOURCE Koha Health

New Name to better represent Company's proprietary technology platform expanded applications beyond orthopedics MONTREAL, Sept. 7, 2022 /PRNewswire/ - Ortho Regenerative Technologies Inc., (CSE: ORTH) ( OTCQB: ORTIF) (" Ortho" or the " Company") a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that it has changed its corporate name to ChitogenX Inc. to better reflect the Company's expanded clinical and commercial opportunities, mission, values, and core competencies. The Company's shares are expected to begin trading on the CSE under the new name and new ticker symbol, CSE: CHGX at market open on or around September 12, 2022. "We evaluated our Company name in light of the vast potential clinical and commercial applications for our proprietary technology platform, and it was obvious that these applications were much broader than just the orthopaedic field the previous corporate name was inferring to", said Philippe Deschamps, CEO. "We opted for a new company name that better represented our identity and expanded possibilities. ChitogenX achieves both". The corporate name change was approved at the last Annual General and Special Meeting of Shareholders held via videoconference on July 21, 2022, following the passing of a special resolution authorizing an amendment to the Company's articles to effect the name change. No action is required by shareholders in connection with the name change, and no change has been made to the Company's share capital. The Company encourages any shareholder with questions to contact their broker or agent. About ChitogenX Inc. ChitogenX Inc. (formally Ortho Regenerative Technologies Inc.) is a clinical stage regenerative medicine company dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. ORTHO-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. ORTHO-R can be directly and easily applied to the site of injury by a surgeon during a routine operative procedure with minimal disruption to length of surgery. ORTHO-R is currently the object of an ongoing U.S. Phase I/II clinical trial for rotator cuff tear repair in 10 U.S. based clinical centers. Other formulations are being developed to leverage the technology's performance characteristics such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease. Further information about Chitogenx is available on the Company's website at and on SEDAR at . Forward-Looking Statements This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. SOURCE Ortho Regenerative Technologies Inc.